SOCIETY LINKS

ICHS and ASTCT partnered to deliver these sessions for the 24th Symposium.

Thank you to ASTCT for this important support and collaboration!

Please see the ICHS Symposium Agenda for these partnered sessions:

Parallel Session (Co-organized with ASTCT TID-SIG)

Interplay Between HHV-6, CMV, EBV, and Other Herpes Viruses
Moderators: Michelle Yong, MBBS, FRACP, MPH, PhD, and Christine Durand, MD
Impact of CMV Prophylaxis on EBV Viremia and PTLD
Per Ljungman, MD, PhD, FIDSA, FESCMID
New Insights into HHV-6 Infections in HCT and CAR-T Recipients
Joshua Hill, MD
CMV Prophylaxis vs Pre-emptive Therapy in SOT recipients: Lessons Learned Over the Years
Atul Humar, MD, MSc, FRCPC

Parallel Session (Co-organized with ESGREV and ASTCT TID-SIG) 

Challenges and Opportunities in Managing RSV, Influenza, and Parainfluenza Virus in Immunocompromised Patients: What are the Guidelines Telling Us?

Moderators: Deepali Kumar and Alpana Waghmare
Shortcomings
Hans Hirsch, MD, MSc
Headwinds
Michael G. Ison, MD, MS

Satellite Symposium: (Co-organised with ASTCT TID-SIG)

Refractory and Resistant HSV Resistant Viral Infections: Headways and Unmet Needs
Moderators: Sanjeet Dadwal, MD, FACP, FIDSA and Zainab Shahid, MD, FACP, FIDSA
Refractory and Resistant HSV Infections: Burden and Opportunities
Genovefa (Zenia) Papanicolaou, MD, FIDSA, FASTCT
Refractory and Resistant CMV Infections: Filling the Gap
Michael Boeckh, MD, PhD

Educational Webinar 

The Management and Prevention of Paramyxoviruses in Hematopoietic Cell Transplantation Recipients Webinar 

This session covered the latest guidelines for managing respiratory syncytial virus (RSV) and other paramyxoviruses, focusing on epidemiology, clinical diagnosis, prophylaxis, and treatment strategies. Experts will discuss special considerations for pediatric, cord blood, haploidentical, and T cell-depleted HCT patients, as well as chimeric antigen receptor T cell therapy recipients.

Learning Objectives:

• Analyze the epidemiological patterns and risk factors of paramyxovirus infections in hematopoietic cell transplantation (HCT) recipients.
• Evaluate and differentiate the key clinical features for diagnosing respiratory syncytiavirus (RSV) and other paramyxovirus infections in HCT patients.
• Apply current prophylaxis and treatment strategies for paramyxovirus infections in HCT recipients, comparing their effectiveness and potential outcomes.
• Synthesize special considerations for paramyxovirus management in specific HCT patient populations, integrating various factors that influence treatment decisions

Panelists:

• Marjorie Vieira Batista, MD, TID, PhD, ACCamargo Cancer Center
• Alpana Waghmare, MD, Department of Pediatrics, University of Washington School of Medicine

Moderators:

• Roy Chemaly, MD, MPH, FIDSA, FACP, FESCMID, Department of Infectious Diseases, MD Anderson Cancer Center
• Diego R Hijano, MD, MSc St. Jude Children's Research

Registration: ASTCT Learning Center: Management and Prevention of Paramyxoviruses in Hematopoietic Cell Transplantation Recipients